Incannex Healthcare Ltd
NASDAQ:IXHL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Incannex Healthcare Ltd
ASX:IHL
|
43.3m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
280.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
275.5B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.4B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.5B EUR |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Incannex Healthcare Ltd
Glance View
Incannex Healthcare Ltd. is a cannabinoid and psychedelic compound medicine development company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The company is a clinical stage pharmaceutical development company. The firm is engaged in developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Its product candidate IHL-42X is developing a combination of acetazolamide and dronabinol to reduce the apnea hypopnea index (AHI), IHL-216A is a combination of isoflurane and CBD to prevent development of traumatic brain injury (TBI)/concussion, HL-675A comprises a combination of hydroxychloroquine and CBD in prevention and treatment of inflammatory lung conditions (ARDS, COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel diseases and Psi-GAD is providing Psychedelic-assisted psychotherapy for Generalized Anxiety Disorder (GAD).
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Incannex Healthcare Ltd is -1 451.3%, which is above its 3-year median of -1 523.3%.
Over the last 3 years, Incannex Healthcare Ltd’s Net Margin has decreased from -571.4% to -1 451.3%. During this period, it reached a low of -1 889.7% on Jun 30, 2022 and a high of -415.3% on Dec 31, 2020.
